RGD Reference Report - Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

Authors: Wicklein, D  Ramos Leal, N  Salamon, J  Thamer, M  Herrmann, H  Valent, P  Schumacher, U  Ullrich, S 
Citation: Wicklein D, etal., PLoS One. 2012;7(2):e30567. doi: 10.1371/journal.pone.0030567. Epub 2012 Feb 14.
RGD ID: 11075098
Pubmed: PMID:22348015   (View Abstract at PubMed)
PMCID: PMC3279340   (View Article at PubMed Central)
DOI: DOI:10.1371/journal.pone.0030567   (Journal Full-text)

We developed a xenograft model of human Chronic Eosinophilic Leukemia (CEL) to study disease progression and remission-induction under therapy with tyrosine kinase inhibitors using imatinib and nilotinib as examples. The FIP1L1/PDGFRA+ human CEL cell lineEOL-1 was injected intravenously into scid mice, and MR imaging and FACS analysis of mouse blood samples were performed to monitor disease development and the effects of imatinib and nilotinib. Organ infiltration was analyzed in detail by immunohistochemistry after sacrifice. All animals developed CEL and within one week of therapy, complete remissions were seen with both imatinib and nilotinib, resulting in reduced total tumor volumes by MR-imaging and almost complete disappearance of EOL-1 cells in the peripheral blood and in tissues. The new model system is feasible for the evaluation of new tyrosine kinase inhibitors and our data suggest that nilotinib may be a valuable additional targeted drug active in patients with FIP1L1/PDGFRA+ CEL.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
myeloid sarcoma treatmentIMP 11075098 RGD 
myeloid sarcoma treatmentISOPDGFRA (Homo sapiens)11075098; 11075098 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Pdgfra  (platelet derived growth factor receptor alpha)

Genes (Mus musculus)
Pdgfra  (platelet derived growth factor receptor, alpha polypeptide)

Genes (Homo sapiens)
PDGFRA  (platelet derived growth factor receptor alpha)


Additional Information